Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System

JAAD International 2026 Open access

Read full text
Authors: Simona Alomary, Nicole J. Baker, Temitayo A. Ogunleye, Susan C. Taylor
DOI: 10.1016/j.jdin.2026.01.007
Cited by: 0
References: 3

Fields of Study & Subjects

Pharmacovigilance and Adverse Drug Reactions Hidradenitis Suppurativa and Treatments Drug-Induced Adverse Reactions

Publication details

Journal / source
JAAD International
Volume
25
Pages
92–94
Publication date
3 February 2026
Language
EN